SCHEMBL17100623

SCHEMBL17100623

Fc1ccccc1CN1CCN(c2nc(Cc3ccc(Cl)cc3)no2)CC1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.57
NPSR1 Q6W5P4 1/20 0.49
POLB P06746 1/20 0.46
ALDH1A1 P00352 9/20 0.45
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
MAPT P10636 4/20 0.45
MEN1 O00255 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
LMNA P02545 3/20 0.44
KDM4E B2RXH2 3/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 3/20 0.43
CYP2A13 Q16696 1/20 0.42
NPC1 O15118 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100743 0.90 ALDH1A1 (0.56) KMT2AALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL17100858 0.87 LMNA (0.57) KMT2ANPSR1ALDH1A1CNR1CNR2
SCHEMBL17100651 0.84 SMN1; SMN2 (0.46) KMT2APOLBALDH1A1MAPTMEN1
SCHEMBL17100819 0.81 MAPT (0.47) KMT2ANPSR1POLBALDH1A1CNR1
SCHEMBL17100853 0.81 NPSR1 (0.52) KMT2ANPSR1POLBALDH1A1MAPT
SCHEMBL17100710 0.81 NPSR1 (0.52) KMT2ANPSR1POLBALDH1A1MAPT
SCHEMBL17100749 0.79 L3MBTL1 (0.43) MAPK1NPC1HTTRAB9AL3MBTL1
SCHEMBL17100670 0.79 L3MBTL1 (0.43) MAPK1NPC1HTTRAB9AL3MBTL1
SCHEMBL17100793 0.79 HTR6 (0.45) KMT2ANPSR1ALDH1A1MAPTMEN1
SCHEMBL17100725 0.78 NPC1 (0.43) KMT2AALDH1A1MAPTMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US claimed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP claimed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT KMT2A 4820/4885NPSR1 2545/4885POLB 2985/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT KMT2A 4819/4885NPSR1 2716/4885POLB 2935/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT KMT2A 4820/4885NPSR1 2545/4885POLB 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.